‘Pharma Bro’ Shkreli Suspended From Twitter For Harassment

‘Pharma Bro’ Shkreli Suspended From Twitter For Harassment

WASHINGTON (Reuters) – Former U.S. drug executive Martin Shkreli, dubbed the “pharma bro” and vilified for raising the price of a lifesaving drug by 5,000 percent, was suspended by Twitter on Sunday for harassing a female journalist.

Shkreli, a supporter of Republican President-elect Donald Trump, had dogged freelance reporter Lauren Duca, including sending her requests for dates, after she wrote an op-ed piece for Teen Vogue that was critical of Trump.

Shkreli, who caused controversy for hiking the price of an anti-parasitic drug to $750 a dose while head of Turing Pharmaceuticals LLC, had his Twitter account suspended for harassment, the San Francisco-based microblogging service said in an emailed statement.

After the suspension, Duca tweeted, “Why is harassment an automatic career hazard for a woman receiving any amount of professional attention?”

Duca had drawn media attention for her article in December arguing that Trump had conned U.S. voters. Shkreli then tweeted about trying to date her, and he sent her an invitation on Thursday to attend Trump’s Jan. 20 inauguration as his guest.

Duca replied on Twitter, “I would rather eat my own organs.”

Shkreli later posted a collage of photos of Duca, and updated his profile picture with a photo of Duca and her husband showing Shkreli’s face superimposed over that of her spouse.

Duca retweeted the pictures on Sunday, asking Twitter founder and Chief Executive Jack Dorsey why they were allowed on the social network. “I feel sick,” she wrote.

Shkreli, who is in his 30s, became known as the “pharma bro” after he taunted detractors who criticized him for increasing the price of the drug Daraprim.

He was forced to step down as Turing chief executive in 2015 amid criminal and civil securities fraud charges alleging he ran a Ponzi-like scheme while at the hedge fund MSMB Capital Management and while he was top executive at Retrophin Inc, another drug company.

Turing is the subject of antitrust probes by the Federal Trade Commission and the New York attorney general’s office stemming from its increase in the Daraprim price.

(Reporting by Ian Simpson; Editing by Daniel Wallis and Alan Crosby)

IMAGE: Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, U.S.,October 14, 2016. REUTERS/Lucas Jackson – RTSSBLL

Advertising

Start your day with National Memo Newsletter

Know first.

The opinions that matter. Delivered to your inbox every morning

Donald Trump
Former President Donald Trump

Imagine this: You’re a clerk to a judge in a New York State court. You graduated from the Cardozo School of Law in 2010, and since then, you have worked as an associate in a New York law firm. For five years, you worked for the City of New York in its Special Litigation Unit handling law suits against the city. You have been the clerk to Judge Arthur Engoron since 2019, getting up in the morning and traveling by subway into Manhattan to your office in his chambers, or sitting beside him in court, advising him on cases, filings, motions – the constant flow of legal documents and questions that any judge in a big city court deals with constantly.

Keep reading...Show less
Trump Touts New Push To 'Repeal And Replace' Obamacare

The late Sen. John McCain gives thumbs down to Affordable Care Act repeal in July 2017

Photo by Library of Congress on Unsplash

Donald Trump is once again living in the past, trying to resurrect a Republican political debacle that even the Freedom Caucus has abandoned: Obamacare repeal. “The cost of Obamacare is out of control, plus, it’s not good Healthcare. I’m seriously looking at alternatives," he spewed on Truth Social on Saturday.

Keep reading...Show less
{{ post.roar_specific_data.api_data.analytics }}